Keymed Biosciences Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Bo Chen
Chief executive officer
CN¥4.8m
Total compensation
| CEO salary percentage | 95.9% |
| CEO tenure | 3.2yrs |
| CEO ownership | n/a |
| Management average tenure | 3.8yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
There's Reason For Concern Over Keymed Biosciences Inc.'s (HKG:2162) Massive 28% Price Jump
May 13
News Flash: 10 Analysts Think Keymed Biosciences Inc. (HKG:2162) Earnings Are Under Threat
Apr 03Keymed Biosciences Inc. (HKG:2162) Just Reported And Analysts Have Been Cutting Their Estimates
Mar 31A Look At The Intrinsic Value Of Keymed Biosciences Inc. (HKG:2162)
Nov 13Analysts Just Made A Noticeable Upgrade To Their Keymed Biosciences Inc. (HKG:2162) Forecasts
Sep 03Broker Revenue Forecasts For Keymed Biosciences Inc. (HKG:2162) Are Surging Higher
Mar 21Companies Like Keymed Biosciences (HKG:2162) Are In A Position To Invest In Growth
Jun 27CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | CN¥5m | CN¥5m | -CN¥359m |
| Sep 30 2023 | n/a | n/a | -CN¥313m |
| Jun 30 2023 | n/a | n/a | -CN¥267m |
| Mar 31 2023 | n/a | n/a | -CN¥287m |
| Dec 31 2022 | CN¥4m | CN¥4m | -CN¥308m |
| Sep 30 2022 | n/a | n/a | -CN¥281m |
| Jun 30 2022 | n/a | n/a | -CN¥253m |
| Mar 31 2022 | n/a | n/a | -CN¥2b |
| Dec 31 2021 | CN¥4m | CN¥4m | -CN¥4b |
| Sep 30 2021 | n/a | n/a | -CN¥4b |
| Jun 30 2021 | n/a | n/a | -CN¥4b |
| Mar 31 2021 | n/a | n/a | -CN¥3b |
| Dec 31 2020 | CN¥231k | CN¥227k | -CN¥819m |
| Dec 31 2019 | CN¥188k | CN¥183k | -CN¥168m |
Compensation vs Market: Bo's total compensation ($USD659.40K) is above average for companies of similar size in the Hong Kong market ($USD486.65K).
Compensation vs Earnings: Bo's compensation has increased whilst the company is unprofitable.
CEO
Bo Chen (49 yo)
3.2yrs
Tenure
CN¥4,788,000
Compensation
Dr. Bo Chen has been executive Director, chairman of Board and chief executive officer at Keymed Biosciences Inc. since April 03, 2021 and served as Director since April 23, 2018 until April 03, 2021. Dr....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & CEO | 3.2yrs | CN¥4.79m | no data | |
| Senior VP & Executive Director | 3.2yrs | CN¥1.61m | no data | |
| Senior VP & Executive Director | 6.1yrs | CN¥2.81m | no data | |
| Senior VP & Non Executive Director | 6.3yrs | CN¥178.00k | no data | |
| CFO, VP & Joint Company Secretary | 3.8yrs | no data | no data | |
| Senior Vice President | 6.3yrs | no data | no data | |
| Joint Company Secretary | 2.3yrs | no data | no data |
3.8yrs
Average Tenure
49yo
Average Age
Experienced Management: 2162's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman & CEO | 6.2yrs | CN¥4.79m | no data | |
| Senior VP & Executive Director | 6yrs | CN¥1.61m | no data | |
| Senior VP & Executive Director | 3.3yrs | CN¥2.81m | no data | |
| Senior VP & Non Executive Director | 6yrs | CN¥178.00k | no data | |
| Independent Non Executive Director | 3.2yrs | CN¥572.00k | no data | |
| Independent Non Executive Director | 3.2yrs | CN¥476.00k | no data | |
| Independent Non-Executive Director | 3.2yrs | CN¥476.00k | no data | |
| Non Executive Director | 3.3yrs | no data | no data | |
| Non Executive Director | 3.3yrs | no data | no data |
3.3yrs
Average Tenure
49yo
Average Age
Experienced Board: 2162's board of directors are considered experienced (3.3 years average tenure).